COO Price Prediction Next Week
Technical Analysis: Based on the latest technical indicators, COO shows bearish signals with RSI at 32.66 indicating near oversold conditions. The stock is trading below all major moving averages (5-day: $92.17, 20-day: $95.24, 200-day: $97.38), suggesting a strong downward trend.
Price Movement Analysis:
- Latest close: $88.13 (Feb 14, 2025)
- Significant drop of 5.96% during regular market hours
- Trading volume increased to 3.05M shares, indicating strong selling pressure
- Currently trading near the lower Bollinger Band ($87.58), suggesting potential oversold conditions
News Impact:
- Recent Q4 earnings release showed mixed results
- Experienced decline in PARAGUARD sales due to competition
- Softness in torics and multifocals demand
- U.S. inventory contraction affecting myopia management sales
Fibonacci Levels:
- Support levels: S1: $88.66, S2: $86.22, S3: $82.27
- Resistance levels: R1: $96.54, R2: $98.98, R3: $102.93
- Pivot point: $92.60
Next Week Price Prediction: Based on technical indicators and recent news sentiment:
- Target price: $85-86 range
- Recommendation: SELL
- Key factors:
- Bearish momentum continuing from recent earnings
- Below all major moving averages
- Negative MACD crossover (-0.85)
- Weak stochastic RSI readings (16.36)
- Ongoing operational challenges likely to pressure stock
The stock is expected to test support at $86.22 (Fibonacci S2) next week, with potential for further downside if this level breaks.
COO Similar Chart Price Prediction
The price of COO is predicted to go up 0%, based on the high correlation periods with FRPT. The similarity of these two price pattern on the periods is 94.87%.
COO
FRPT
Up: 0%Similarity: 94.87%
COO Revenue Forecast
COO EPS Forecast
COO FAQs
What is bull’s view on COO?
What is bear's view on COO?
What is COO revenue forecast for next quarter？
What is COO eps forecast for next quarter？
COO VS S&P500
Cooper is one of the leading visioncare companies in the world with a proven record of successful product development. It will continue to launch technically superior products over the long term.
With an increasing prevalence of myopia, especially in children, MiSight and the joint venture with EssilorLuxottica will place Cooper as the leading player in myopia management.
Favorable global trends such as an aging population, women having children at a later age, and an increasing awareness of women's health will expand CooperSurgical's end markets.
